Delving into the Latest Updates on Prolysis Ltd. with Synapse

Overview

ABSTRACTTo address the need for new antibacterials, a number of bacterial genomes have been systematically disrupted to identify essential genes. Such programs have focused on the disruption of single genes and may have missed functions encoded by gene pairs or multiple genes. In this work, we hypothesized that we could predict the identity of pairs of proteins within one organism that have the same function. We identified 135 putative protein pairs inBacillus subtilisand attempted to disrupt the genes forming these, singly and then in pairs. The single gene disruptions revealed new genes that could not be disrupted individually and other genes required for growth in minimal medium or for sporulation. The pairwise disruptions revealed seven pairs of proteins that are likely to have the same function, as the presence of one protein can compensate for the absence of the other. Six of these pairs are essential for bacterial viability and in four cases show a pattern of species conservation appropriate for potential antibacterial development. This work highlights the importance of combinatorial studies in understanding gene duplication and identifying functional redundancy.

100 Deals associated with Prolysis Ltd.

Login to view more data

100 Translational Medicine associated with Prolysis Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GYR-767 series (Aviragen Therapeutics) ( ATPase x Bacterial DNA gyrase x Topoisomerase IV )	Bacterial Infections More	Discontinued
GYR-777 series (Biota) ( ATPase x Bacterial DNA gyrase x Topoisomerase IV )	Skin Diseases, Bacterial More	Discontinued
ANN-855	Bacterial Infections More	Pending
CDI-538 ( FtsZ x Tubulin )	Bacterial Infections More	Pending
MUR-807	Respiratory Tract Infections More	Pending